New data from LEADER, a a Phase II study of Victoza (liraglutide), from Novo Nordisk, published in the Journal of...
Novo Nordisk announced that the progression of kidney damage was significantly lower with Victoza (liraglutide) treatment vs placebo, as measured...
Novo Nordisk announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the FDA has completed its meeting regarding...
eFFECTOR Therapeutics, Inc. a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, announced topline results from the primary analysis of the randomized Phase II KICKSTART trial which tested tomivosertib or placebo, each combined with pembrolizumab, as frontline treatment for patients with non-small cell lung cancer (NSCLC) with PD-L1 ?50%.
This trial is conducted in Africa, Asia, Europe, and North and South America. The aim of this trial is to determine the long term effect of liraglutide on cardiovascular events in subjects with type 2 diabetes.
Sorin S.p.A. a global medical device company and a leader in the treatment of cardiovascular diseases, and Cyberonics Inc. a...
Baxter International highlighted a report from KLAS that named the Sigma Spectrum Infusion System the leader among all large-volume infusion...